The pros and cons of “screening” for prostate cancer

A newly published article by Shoag et al. in the New England Journal of Medicine (NEJM) has suggested that the risks associated with “screening” for prostate cancer using the PSA test may not be as high as previously suggested. … READ MORE …

Survival of men with metastatic, castration-resistant prostate cancer

There has been regular discussion here and elsewhere about the degree to which new forms of therapy have impacted patient survival since the original approval of docetaxel for treatment of metastatic, castration-resistant  prostate cancer (mCRPC). … READ MORE …

Prostate ablation using HIFU — the role of patient preference information

A newly published review by staff of the Center for Devices and Radiological Health (CDRH at the U.S. Food & Drug Administration (FD) addresses the potential role for patient preference information (PPI) in determining patient perceptions of the “value” of high-intensity focused ultrasound (HIFU) and similar techniques in the management of prostate cancer. … READ MORE …

Are we all talking about AS the same way? Not yet!

An interesting new article in The ASCO Post tells us almost as much about the physicians who treat prostate cancer as it does about the options that are available to patients. … READ MORE …

Patients’ understanding of the risks and benefits of first-line treatment

A newly published article in BJU International has (finally) proven something many prostate cancer educators and advocates have known for years: many patients have a very poor appreciation of the risks and benefits of their differing treatment options at the time they make decisions about first-line treatment for localized prostate cancer. … READ MORE …

An update on “screening” for prostate cancer: four perspectives

To quote the abstract of the paper discussed below, the use of the PSA test to screen for risk of prostate cancer “in men at normal risk of prostate cancer is one of the most contested issues in cancer screening.” No! Really? … READ MORE …

Kaiser reports on quality of life outcomes after first-line treatment for prostate cancer

Kaiser Permanente maintains a large data registry in  order to assess the quality of outcomes over time among tens of thousands of Kaiser patients, prostate cancer patients included. … READ MORE …

And now … data from the PCLO trial at 15 years …

A new update on the prostate cancer outcomes of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial has given us a rather different interpretation of the meaning of the data from this trial — although whether that “meaning” actually has “meaning” is probably up for debate. … READ MORE …

New immunotherapeutics aren’t working well when combined with standard forms of care

A newly published article in the journal Science Translational Medicine has questioned the merits of treating prostate cancer patients with immunotherapies while they are simultaneously being treated with medical forms of castration (androgen deprivation therapy or ADT), chemotherapy, and/or radiation therapy. … READ MORE …

And back to the screening controversy, yet again …

Four very recent articles and presentations have addressed issues relevant to the use of the PSA test in testing/screening for risk of prostate cancer. … READ MORE …

Testosterone treatment in aging men with hypogonadism

Testosterone levels tend to fall in most men as we age. This is hardly new information! An article this week in the New England Journal of Medicine suggests that treatment with testosterone gels is appropriate for aging men with low testosterone levels (hypogonadism). … READ MORE …

USPSTF to re-assess harms and benefits of PSA-based screening for risk of prostate cancer

Yesterday the U.S. Preventive Services Task Force (USPSTF) posted detailed information about a new draft research plan related to screening for prostate cancer. … READ MORE …

Assessing the “value” of new drugs in the treatment of [prostate] cancer

Yesterday the American Society of Clinical Oncology (ASCO) issued the initial draft of “a conceptual framework for assessing the value of new cancer therapies based on treatment benefits, toxicities, and costs.” ASCO is interested in getting feedback from its members and from the patient community too. … READ MORE …

“Psychosocial interventions in prostate cancer offer limited benefits”

The heading above is the title of a Reuters-generated article on the Medcape Oncology web site. The article is based on a new review article just published in BJU International. … READ MORE …

Is treatment with degarelix really “better” than treatment with an LHRH agonist?

One of our regular readers has asked us to comment on a paper suggesting the possibility of “significant improvement” in various outcomes for men initially treated with the LHRH antagonist degarelix as compared to the LHRH agonists leuprolide acetate and goserelin acetate. … READ MORE …